Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

This study has been completed.
Sponsor:
Information provided by:
MediWound Ltd
ClinicalTrials.gov Identifier:
NCT00324311
First received: May 10, 2006
Last updated: May 8, 2011
Last verified: July 2009
  Purpose

Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed "debridement".

The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications.

The objective of this study is to evaluate the safety and enzymatic debriding efficacy of Debrase Gel Dressing (DGD) in hospitalized patients with deep partial thickness and/or full thickness thermal burns and to compare DGD to standard of care (SOC).


Condition Intervention Phase
Burn
Drug: DGD
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Enzymatic Debridement in Burns Patients (Children & Adults): A Comparison to Standard of Care (Protocol MW 2004-11-02)

Resource links provided by NLM:


Further study details as provided by MediWound Ltd:

Primary Outcome Measures:
  • Co-primary: % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, of deep partial wounds [ Time Frame: Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups) ] [ Designated as safety issue: No ]
  • Co-primary: % treated wound autografted of deep partial wounds [ Time Frame: Post-debridement autografts ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • % treated wound excised (by tangential/minor/Versajet excision) or dermabrasion, in first surgery, for all wounds [ Time Frame: As for primary endpoint ] [ Designated as safety issue: No ]
  • Time to complete wound closure [ Time Frame: % epithelialization assessed post-debridement at weekly intervals until all a patient's wounds closed ] [ Designated as safety issue: No ]
  • Timely eschar removal [ Time Frame: Debridement procedures ] [ Designated as safety issue: No ]
  • Blood loss [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Enrollment: 182
Study Start Date: December 2005
Study Completion Date: February 2010
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DGD Drug: DGD
Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
Active Comparator: SOC Drug: DGD
Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.

Detailed Description:

Completed study.

  Eligibility

Ages Eligible for Study:   4 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females between 4 years to 55 years of age,
  2. Thermal burns caused by fire/flame, scalds or contact,
  3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5% and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive study treatment,
  4. At least one wound of ≥ 2% TBSA deep partial thickness and/or full thickness burn,
  5. Total burn wounds ≤ 30% TBSA,
  6. Signed written informed consent.

Exclusion Criteria:

  1. Deep partial thickness and/or full thickness facial burn wounds, > 0.5% TBSA; study treatment of facial burns is not allowed,
  2. Study treatment of perineal and/or genital burns (A patient with these wounds may be enrolled but the wounds may not be designated as target wounds),
  3. Circumferential anterior/posterior trunk full thickness fire/flame burns, > 15% TBSA, (Circumferential is defined as encircling ≥ 80% of the trunk circumference.)
  4. Pre-enrollment escharotomy,
  5. Heavily contaminated burns or pre-existing infections,
  6. Signs that may indicate smoke inhalation,
  7. General condition of patient would contraindicate surgery,
  8. Pregnant women (positive pregnancy test) or nursing mothers,
  9. Poorly controlled diabetes mellitus (HbA1c>9%),
  10. Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension, COPD or pre-existing oxygen-dependent pulmonary diseases),
  11. Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema, surgery to the regional lymph nodes, obesity, varicose veins),
  12. Immediate life threatening conditions (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or neoplastic disease),
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00324311

Locations
Australia, Western Australia
Royal Hospital Perth
Perth, Western Australia, Australia
Brazil
Pronto Socorro para Queimaduras de Goiania
Goiania, Brazil
Hospital do Servidor Publico do Estado de Sao Paulo
Sao Paulo, Brazil
France
Centre Hospitalier Regional et Universitaire de Marseille, Service de Chirurgie Plastique Reparatrice et Esthetique
Marseille, France, 13005
Center Des Brules Hopital Cochin
Paris, France, F-75014
Germany
Unfallkrankenhaus Berlin Burn Center
Berlin, Germany
BG - Unfallklinik Ludwigshafen
Ludwigshafen, Germany
Klinikum Mannheim Universtatsklinikum
Mannheim, Germany
Israel
Soroka University Medical Center
Beer Sheba, Israel
Italy
Centro Grandi Ustionati
Cesena, Italy, 47023
Direttore U.O. Chirurgia Plastica e Centro Ustioni Ospedale Civico
Palermo, Italy, 90127
Poland
Wojskowy Instytut Medyczny
Warsaw, Poland
Romania
Emergency Clinic Hospital "Bagdazar-Arsenie"
Bucharest, Romania
Slovakia
Center for Burns & Reconstructive Surgery, University Hopsital Bratislava
Bratislava, Slovakia, 82107
Clinic of Burns and Reconstructive Surgery Hospital Kosice
Kosice-Saca, Slovakia, 04015
United Kingdom
Queen Victoria Hospital
East Grinstead, United Kingdom, RH19 3DZ
The Burn Center Pinderfields Hospital
Wakefield, United Kingdom, WF1 4EE
Sponsors and Collaborators
MediWound Ltd
Investigators
Study Chair: Lior Rosenberg, MD MediWound Ltd
  More Information

Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Siyu Liu, Vice President, North American Innovative Research & Development and Head of Global Clinical Operations ), Teva Neuroscience
ClinicalTrials.gov Identifier: NCT00324311     History of Changes
Other Study ID Numbers: MW2004-11-02
Study First Received: May 10, 2006
Last Updated: May 8, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Israel: Ministry of Health

Additional relevant MeSH terms:
Burns
Wounds and Injuries

ClinicalTrials.gov processed this record on October 01, 2014